StonvexLoading…
StonvexStonvexStonvexCore line items from CTS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-07-22 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $146.11M | $139.23M | $541.32M | $404.05M | $261.08M |
Operating Income | Not available | $21.98M | $82.64M | $59.95M | $39.02M |
Net Income | Not available | $17.20M | $65.32M | $45.58M | $18.53M |
EPS (Diluted) | $0.61 | $0.59 | $2.19 | $1.52 | $1.06 |
Total Assets | Not available | $777.15M | $764.31M | $790.37M | $784.73M |
Total Liabilities | Not available | $219.68M | $212.53M | $242.72M | $234.57M |
Cash & Equivalents | Not available | $90.85M | $82.30M | $110.30M | $99.44M |
Free Cash Flow OCF − CapEx | Not available | $12.30M | $86.37M | $60.35M | $36.13M |
Shares Outstanding | Not available | 28.62M | 28.76M | 29.15M | 29.55M |